FIRST-IN-HUMAN PHASE 1 STUDY OF EA3571, WHICH IS A NOVEL DUAL INHIBITOR OF ENTEROPEPTIDASE AND TRYPSIN WITH LUMINAL ACTION, IN HEALTHY ADULT PARTICIPANTS

被引：0
|
作者：
Umeda, Atsushi [1 ]
Owada, Yasuko [2 ]
Furihata, Kenichi [3 ]
Tsuruoka, Shuichi [4 ]
Nakajima, Atsushi [5 ]
Mikami, Ryosuke [1 ]
Oaku, Masakaze [1 ]
Yamamoto, Takuya [1 ]
Yano, Tetsuo [1 ]
Kumagai, Yuji [6 ]
机构：
[1] EA Pharma Co Ltd, Tokyo, Japan
[2] OPHAC Hosp, Osaka, Japan
[3] P One Clin, Tokyo, Japan
[4] Tajirigaoka Hosp, Yokohama, Kanagawa, Japan
[5] Yokohama City Univ, Yokohama, Kanagawa, Japan
[6] Kitasato Inst Hosp, Tokyo, Japan
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
592
引用
收藏
页码：S433 / S434
页数：2
相关论文
共 50 条
  • [1] PHARMACOLOGICAL CHARACTERIZATION OF EA3571: A NOVEL DUAL INHIBITOR OF ENTEROPEPTIDASE AND TRYPSIN WITH LUMINAL ACTION FOR METABOLIC DYSFUNCTIONASSOCIATED STEATOHEPATITIS
    Andou, Ayatoshi
    Yamaura, Yui
    Kaneko, Masahiko
    Sen Takeshita
    HEPATOLOGY, 2024, 80 : S30 - S31
  • [2] First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
    Koiwa, Fumihiko
    Yazawa, Rie
    Fukagawa, Masafumi
    Honda, Daisuke
    Akizawa, Tadao
    DRUGS IN R&D, 2022, 22 (02) : 131 - 140
  • [3] First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
    Fumihiko Koiwa
    Rie Yazawa
    Masafumi Fukagawa
    Daisuke Honda
    Tadao Akizawa
    Drugs in R&D, 2022, 22 : 131 - 140
  • [4] Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers
    Richard, Frank
    van Lier, Jan Jaap
    Roubert, Bernard
    Haboubi, Teba
    Gohring, Udo-Michael
    Durrenberger, Franz
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (01) : 68 - 77
  • [5] Tolerability and kinetics of SYNB1020 in a Phase 1, first-in-Human, healthy adult volunteer study
    Puurunen, M.
    Denney, W. S.
    Blankstein, L.
    Goldwater, R.
    Parsons, T.
    Millet, Y.
    Kurtz, C.
    Brennan, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S737 - S737
  • [6] PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY
    Mendell, J.
    Gewitz, A.
    Wang, Y.
    Harnisch, L.
    Olenchock, B.
    Pan, H.
    Podgrabinska, S.
    Zheng, W.
    Zhao, A.
    Vanhoutte, F.
    Davis, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S67 - S68
  • [7] A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
    Yang, Xin-Mei
    Yang, Yang
    Yao, Bu-Fan
    Ye, Pan-Pan
    Xu, Yan
    Peng, Shao-Ping
    Yang, Yu-Mei
    Shu, Pan
    Li, Pei-Jin
    Li, Shan
    Hu, Hong-Lin
    Li, Qian
    Song, Lin-Lin
    Chen, Ke-Guang
    Zhou, Hai-Yan
    Zhang, Ye-Hui
    Zhao, Fu-Rong
    Tang, Bo-Hao
    Zhang, Wei
    Zhang, Xin-Fang
    Fu, Shu-Meng
    Hao, Guo-Xiang
    Zheng, Yi
    Shen, Jing-Shan
    Xu, Ye-Chun
    Jiang, Xiang-Rui
    Zhang, Lei-Ke
    Tang, Ren-Hong
    Zhao, Wei
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 191
  • [8] Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study
    Miyamoto, Kyoko
    Miller, Robert M.
    Voors-Pette, Christine
    Oosterhaven, Jart A. F.
    van den Dobbelsteen, Marieke
    Mihara, Katsuhiro
    Geldof, Marian
    Sato, Yuji
    Matsuda, Naomi
    Kirita, Shirou
    Sawa, Masaaki
    Arimura, Akinori
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (11):
  • [9] A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants
    Lim, Chay Ngee
    Kantaridis, Constantino
    Huyghe, Isabelle
    Gorman, Donal
    Berasi, Stephen
    Sonnenberg, Gabriele E.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (04):
  • [10] A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation
    Daniel, Weston L. L.
    Lorch, Ulrike
    Mix, Scott
    Bexon, Alice S. S.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345